ImmuDyne Provides 2017 Business Outlook
March 06 2017 - 9:05AM
ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader
in the development and marketing of OTC health and wellness
products addressing large unmet needs, today issued its 2017
business outlook to provide an overview of anticipated events and
key milestones for the coming year, as well as a look back at
business highlights from 2016.
ImmuDyne has experienced significant revenue growth over the
past 2 years. While some of this growth came from our Beta
Glucan raw material business, most came from the launch and rapid
growth of our direct-to-consumer sales operation. ImmuDyne’s
top line revenue grew from $714,000 in 2014 to $1,250,000 in 2015
and is expected to be reported at over $5,000,000 in 2016.
Management believes 2017 will be a transformative year in many
ways.
ImmuDyne accomplished the following in
2016:
- Scaled our direct to consumer skincare line from $0 to over
$4.0M in top-line revenue. We accomplished this with very
little dilution to our shareholders – roughly $500k in outside
investment raised at $0.23 per share. We believe we can
continue to scale our business in the same fashion with minimal
ongoing dilution.
- Invested in our direct-marketing infrastructure to facilitate
future growth. This includes office space in ImmuDyne PR, which now
includes over 10 key employees and a call center operation that
enables us to better serve our customers and enhance profitability.
- Reformulated our Inate MD skincare line with a leading
organic-certified and OTC registered skincare contract
manufacturer. This has resulted in a superior product that we
believe will increase our customer retention and profitability.
- Invested in an independently owned fulfillment center in
Pennsylvania that has greatly improved the efficiency of our
shipping operation and most importantly the customer experience
when they receive our products.
- Developed an Instant Wrinkle Eraser product that is now part of
our product portfolio. Initial indications are that this
potentially will be a very successful product and a meaningful part
of ongoing revenue.
- In-licensed a patented hair loss shampoo and conditioner from
Dr. Steven Shapiro and Dr. Michael Borenstein, two opinion leading
dermatologists in West Palm Beach, Florida. We’ve invested
heavily in brand development for this product line and have hired a
highly regarded direct-marketing agency to assist with final stages
of launch.
- Commissioned a controlled clinical study on one of our Yeast
Beta Glucan ingredients which demonstrated a positive effect on
Langerhans cell activity, as well as protecting skin from UV rays
and pollutants.
Our goal for the remainder of 2017 is to focus on profitably
scaling our Inate MD product line and to initial launch and growth
of the Shapiro MD line. Additionally, we believe there is a
significant market opportunity for our Yeast Beta Glucan
nutritional supplement which we will continue to grow alongside of
our core products.
In Q4 2016 and Q1 2017 we began investing time and resources
into an internal media buying strategy which we felt was essential
to the Company’s long term success. Relying solely on third party
exchanges for customer acquisition, as we did in 2016, created
artificially high customer acquisition costs and a lower quality,
and a less profitable customer. We believe that our internal media
strategy will add significant value to our business, and reduce our
customer acquisition costs by nearly 50% from 2016 levels, as we
enter into Q2 2017 and beyond. In addition, initial indications are
that customers acquired internally are more valuable and have
greater retention than customers that are acquired through third
parties. This equates to greater earnings for our
shareholders and more scalability overall for the business.
We will be formally launching the Shapiro MD (www.shapiromd.com)
hair loss product line in the coming weeks. This patented,
proprietary, dermatologist developed hair loss product line has
huge market potential around the world. Because of the
significant investment we have made in infrastructure over the past
12 months, we have the ability to quickly scale this product line
which could have a positive near-term effect on earnings.
Following the initial online launch, we are planning a national
infomercial campaign and retail placement strategy. We have
already received inquiries from several national and international
distributors that wish to sell the product once it’s available.
Lastly and most importantly, ImmuDyne’s management will continue
to demonstrate to shareholders that our economic interests are
identical. All key employees at ImmuDyne work primarily for equity,
not cash compensation. The combined cash salaries of all senior
management is less than $20,000 per month. Management, affiliates,
and their family members own more than 60% of ImmuDyne’s common
stock and like you, have a large, ongoing interest in ImmuDyne's
success.
Thank you for being a shareholder of ImmuDyne. Please feel free
to reach out to our Investor Relations team at
investors@immudyne.com with any additional questions you may
have.
Sincerely,
Mark McLaughlinPresident & CEO
Stefan GalluppiChief Operating Officer
About lmmuDyne
lmmuDyne, Inc. (the "Company") is a health and wellness company
which develops, manufactures, markets, and sells innovative
lifestyle products. The Company's lead products contain its
proprietary yeast beta glucans that have been shown through testing
and analysis to support the immune system. The Company's products
include once a day oral intake capsules as well as topical serums
and creams for skin application. lmmuDyne also has developed a
proprietary natural delivery technology for potential new market
opportunities. All of lmmuDyne's intellectual property is protected
by patents and/or trade secrets. Additional information can be
found on the web at www.immudyne.com.
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe
Harbor Act Disclaimer: Forward looking statements in this release
are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. Certain statements in
this press release, including projections with respect to
lmmuDyne's results of operations, may contain words such as
"anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "projects," "plans," "targets" and other similar
language and are considered forward-looking statements. These
statements are based on management's current expectations,
estimates, and forecasts. These forward-looking statements are
subject to important assumptions, risks and uncertainties, which
are difficult to predict and therefore the actual results may be
materially different from those discussed.
Contact:
ImmuDyne, Inc.
Mark McLaughlin: +1-914-714-8901